Cargando…

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma

Soft tissue sarcomas are a group of rare and aggressive connective tissue neoplasms for which curative therapeutic opportunities are limited in advanced phase. Clinical trials assessing immunotherapy in these tumors have so far reported limited efficacy. The objective of this study is to provide a d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dufresne, A., Lesluyes, T., Ménétrier-Caux, C., Brahmi, M., Darbo, E., Toulmonde, M., Italiano, A., Mir, O., Le Cesne, A., Le Guellec, S., Valentin, T., Chevreau, C., Bonvalot, S., Robin, Y.M., Coindre, J-M, Caux, C., Blay, J.Y., Chibon, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458655/ https://www.ncbi.nlm.nih.gov/pubmed/32923153 http://dx.doi.org/10.1080/2162402X.2020.1792036

Ejemplares similares

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment
por: Ménétrier-Caux, Christine, et al.
Publicado: (2012)

MDR1 in immunity: friend or foe?
por: Bossennec, Marion, et al.
Publicado: (2018)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas
por: Darmusey, Lucie, et al.
Publicado: (2021)

Renal cell carcinoma induces interleukin 10 and prostaglandin E(2) production by monocytes
por: Ménétrier-Caux, C, et al.
Publicado: (1999)

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
por: Ménétrier-Caux, Christine, et al.
Publicado: (2019)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients
por: Bachelot, T, et al.
Publicado: (2003)

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
por: Bachelot, T, et al.
Publicado: (2006)

ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells
por: Faget, Julien, et al.
Publicado: (2013)

Plasmacytoid dendritic cells deficient in IFNα production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients
por: Sisirak, Vanja, et al.
Publicado: (2013)

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)
por: Moreau-Bachelard, C., et al.
Publicado: (2022)

Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial
por: Filleron, Thomas, et al.
Publicado: (2020)

A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
por: Burlion, Aude, et al.
Publicado: (2019)

The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
por: Lesluyes, Tom, et al.
Publicado: (2017)

Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment
por: Feng, Xiaolan, et al.
Publicado: (2023)

Immune cell dysfunctions in breast cancer patients detected through whole blood multi-parametric flow cytometry assay
por: Verronèse, E., et al.
Publicado: (2015)

Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis
por: Debaudringhien, M., et al.
Publicado: (2022)

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
por: Vigano, Selena, et al.
Publicado: (2019)

Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome
por: Benhaddou, Ataaillah, et al.
Publicado: (2021)

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management
por: Dômont, J, et al.
Publicado: (2010)

Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases
por: Hocar, O., et al.
Publicado: (2012)

Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group
por: Khalifa, J., et al.
Publicado: (2015)

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
por: Le Cesne, A., et al.
Publicado: (2023)

Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
por: Cinier, Justine, et al.
Publicado: (2021)

Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
por: Dufresne, A., et al.
Publicado: (2023)

Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion
por: Merle, Candice, et al.
Publicado: (2020)

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin
por: Laroche, Audrey, et al.
Publicado: (2015)

Options thérapeutiques de prise en charge des sarcomes durant la pandémie COVID-19 : propositions du groupe sarcome français
por: Penel, Nicolas, et al.
Publicado: (2020)

CD73 expression and clinical significance in human metastatic melanoma
por: Monteiro, Inês, et al.
Publicado: (2018)

Cell–cell fusion of mesenchymal cells with distinct differentiations triggers genomic and transcriptomic remodelling toward tumour aggressiveness
por: Delespaul, Lucile, et al.
Publicado: (2020)

Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades
por: Toulmonde, Maud, et al.
Publicado: (2023)

Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence
por: Michot, Audrey, et al.
Publicado: (2023)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Ovarian carcinoma histotype in Lynch syndrome
por: Gilks, C. Blake, et al.
Publicado: (2017)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
por: Roulleaux Dugage, Matthieu, et al.
Publicado: (2021)

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials
por: Nassif, E.F., et al.
Publicado: (2022)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qbsg7t96rg4m931sg1dlb8fk9l